Related Experiment Video
Updated: Feb 2, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung
Mong-Wei Lin1, Kang-Yi Su2, Te-Jen Su3
1Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Objective:
Histologic transformation from adenocarcinoma to small cell lung cancer (SCLC) is one of the mechanisms of acquired resistance after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. Furthermore, de novo combined SCLC/non-small cell lung cancer (NSCLC) have occasionally been reported; however, their mutational statuses and clinicopathological features have not yet been elucidated. In this study, we aimed to profile the genetic backgrounds of these 2 different histologic components by investigating patients with de novo combined SCLC/NSCLC as well as those with lung adenocarcinoma who experienced SCLC transformation after TKI treatment.
Materials And Methods:
Four patients with de novo combined SCLC/NSCLC were investigated, as were 4 other patients with lung adenocarcinoma who experienced SCLC transformation after TKI treatment. The different histologic components of the tumors in each patient were tested for thyroid transcription factor-1, p40, synaptophysin, chromogranin A, p53, retinoblastoma protein (Rb), and achaete-scute homolog 1 (ASCL1) via immunohistochemistry, and were macroscopically dissected for mutational analysis using next-generation sequencing with the Oncomine Focus Assay and Comprehensive Assay panel.
Results:
The distinct histologic components in patients with de novo combined SCLC/NSCLC and those with adenocarcinoma exhibiting small cell transformation showed high consistency in EGFR/TP53/RB1 mutations, and expression patterns of p53 and Rb. A high frequency of activating mutations involving PI3K/AKT1 signaling pathway was observed in SCLC. Nuclear ASCL1 expression was present in SCLC but absent or barely present in adenocarcinoma in 7 cases.
Conclusions:
Our data imply that inactivation of TP53/RB1 function is a possible early event in the histogenesis of synchronous and metachronous SCLC/NSCLC. Moreover, the non-adenocarcinoma (SCLC) component might arise from the adenocarcinoma (NSCLC) component through a mechanism that involves the activation of the ASCL1 and PI3K/AKT1 signaling pathways.
Insights
Small cell lung cancer (SCLC) transformation in lung adenocarcinoma, often linked to EGFR tyrosine kinase inhibitor (TKI) resistance, may involve ASCL1 and PI3K/AKT1 pathway activation. Inactivation of TP53/RB1 is a potential early event in SCLC/NSCLC development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Histologic transformation from adenocarcinoma to small cell lung cancer (SCLC) is a known resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
- De novo combined SCLC/non-small cell lung cancer (NSCLC) cases have been reported, but their genetic profiles and clinical features remain unclear.
Purpose of the Study:
- To investigate the mutational status and clinicopathological features of de novo combined SCLC/NSCLC.
- To compare the genetic backgrounds of de novo combined SCLC/NSCLC with lung adenocarcinoma that transformed to SCLC after TKI treatment.
Main Methods:
- Immunohistochemistry was used to assess markers (TTF-1, p40, synaptophysin, chromogranin A, p53, Rb, ASCL1) in distinct histologic components.
- Next-generation sequencing (Oncomine Focus Assay and Comprehensive Assay) was performed on macroscopically dissected tumor components for mutational analysis.
Main Results:
- High consistency in EGFR/TP53/RB1 mutations and p53/Rb expression was observed between distinct histologic components in both de novo and transformed SCLC/NSCLC.
- Activating mutations in the PI3K/AKT1 signaling pathway were frequent in the SCLC component.
- Nuclear ASCL1 expression was predominantly found in SCLC, but not in adenocarcinoma.
Conclusions:
- Inactivation of TP53/RB1 function may be an early event in the development of synchronous and metachronous SCLC/NSCLC.
- The SCLC component might originate from the NSCLC component, potentially involving activation of ASCL1 and PI3K/AKT1 signaling pathways.
Related Concept Videos
Lung Capacity
Cancer Cell Migration through Invadopodia
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Genomics
Evolutionary Relationships through Genome Comparisons
Pleura of the Lungs

